Figure 5: Next-Generation POCT Sensing Strategies

(A) Synthetic urinary biomarkers are being developed to augment endogenous biomarkers and enable noninvasive monitoring of intravascular thrombosis. A peptide conjugated to a nanoparticle is cleaved in the presence of thrombin and liberates a peptide fragment that is cleared by the kidney and can be detected in the urine. (B) Microfluidic continuous biomarker monitoring devices allow analytes to diffuse from blood to an electrochemical sensing surface modified with aptamers that reversibly bind them enabling continuous monitoring.



Elsevier user license